Translational Development Acquisition Corp.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
TDAC$10.88+0.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2025 and 2024
BALANCE SHEETS
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| | | | | | | |
| ASSETS · · · · | ||||||
| Current assets · · · · | ||||||
| Cash | | $29,787 | | $438,174 | ||
| Prepaid expenses | | 9,678 | | 212,059 | ||
| Total Current Assets | | 39,465 | | 650,233 | ||
| | | | | | | |
| Marketable securities held in Trust Account | | 181,657,311 | | 174,350,346 | ||
| TOTAL ASSETS | | $181,696,776 | | $175,000,579 | ||
| | | | | | | |
| LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS’ DEFICIT | | | | | ||
| Current liabilities | | | | | ||
| Accounts payable and accrued expenses | | $162,311 | | $16,189 | ||
| Due to Sponsor | | 106,762 | | 2,000 | ||
| Promissory note – related party | | | 200,000 | | | — |
| Accrued offering costs | | 75,000 | | 192,114 | ||
| Total Current Liabilities | | 544,073 | | 210,303 | ||
| Deferred underwriting fee | | 6,037,500 | | 6,037,500 | ||
| TOTAL LIABILITIES | | 6,581,573 | | 6,247,803 | ||
| | | | | | | |
| Commitments and Contingencies (Note 6) | | | | | ||
| Class A ordinary shares subject to possible redemption, $0.0001 par value; 17,250,000 shares issued and outstanding at redemption value of $10.53 and $10.11 per share as of December 31, 2025 and 2024, respectively | | 181,657,311 | | 174,350,346 | ||
| | | | | | | |
| SHAREHOLDERS’ DEFICIT | | | | | ||
| Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as of December 31, 2025 and 2024, respectively | | — | | — | ||
| Class A ordinary shares, $0.0001 par value; 100,000,000 shares authorized; no shares issued or outstanding (excluding 17,250,000 shares subject to possible redemption) as of December 31, 2025 and 2024, respectively | | — | | — | ||
| Class B ordinary shares, $0.0001 par value; 10,000,000 shares authorized; 4,657,500 shares issued and outstanding as of December 31, 2025 and 2024, respectively | | 466 | | 466 | ||
| Additional paid-in capital | | — | | — | ||
| Accumulated deficit | | (6,542,574) | | (5,598,036) | ||
| Total Shareholders’ Deficit | | (6,542,108) | | (5,597,570) | ||
| Total Liabilities, Class A Ordinary Shares Subject to Possible Redemption, and Shareholders’ Deficit | | $181,696,776 | | $175,000,579 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.